Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4510 Follow-up analysis of group nutritional education in patients with neuroendocrine neoplasms (GEDNEN Course): A novel approach with proven acceptability

Introduction: Structured group education demonstrates improved outcomes in peri-operative health optimisation and diabetes mellitus. We devised and delivered a novel in person nutrition/dietary education programme for patients with neuroendocrine neoplasms (NENs) at the Sheffield ENETS Centre of Excellence.

Conference:

Presenting Author: Munir A

Authors: Wen Loh E, Walsh E, Bisson H, Ahmed Z, Dancyger-Stevens L,

Keywords: Group Education, Nutrition, Neuroendocrine Neoplasm, Novel Tool,

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,

#4186 The effect of the Covid-19 pandemic on the body composition of patients with gastroenteropancreatic neuroendocrine tumors using a somatostatin analogue

Introduction: The Covid-19 pandemic and its restrictions had a negative impact on the general population. Due to lockdowns, food intake increased and exercise decreased. This led to weight gain and changes in body composition. Hospitals reviewed patients (pts) remotely. The effect of the Covid-19 pandemic has not been described in pts with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogue (SSA).

Conference:

Presenting Author: Clement D

Authors: Clement D, Brown S, Dolly S, Mestre-Alagarda C, Giovos G,

Keywords: GEP-NET, SSA, malnutrition, Covid-19 pandemic,

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,